|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), human kallikrein 2 (hK2), prostate stem cell antigen (PSCA), and differential display code 3 (DD3) in 2215 LNs isolated from 120 patients with localized prostate cancer were assessed by fully quantitative real-time RT-PCR.
|
21600799 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study compared <sup>68</sup>Gallium-prostate-specific-membrane-antigen based Positron-emission-tomography (<sup>68</sup>Ga-PSMA-PET) and <sup>99metastable</sup>technetium-3,3-diphospho-1,2-propanedicarbonacid (<sup>99m</sup>Tc-DPD-SPECT) in performing skeletal staging in prostate cancer (PC) patients and evaluated the additional value of the information from low-dose-computed tomography (CT).
|
28779400 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA levels as a predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer?
|
29745629 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first reports on safety and efficacy of Lu-PSMA have been retrospective series of men with advanced prostate cancer who previously failed conventional therapies and received Lu-PSMA on compassionate basis.
|
29278583 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radioisotope-labeled prostate-specific membrane antigen (PSMA) tracers have been proven accurate for detection of prostate cancer localizations.
|
28825951 |
2017 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b><sup>68</sup>Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (<i>n</i> = 25), primary diagnosis (<i>n</i> = 10), biochemical persistence after primary therapy (<i>n</i> = 5), or staging of known metastatic disease (<i>n</i> = 10).
|
28408531 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, absence of appropriate biomarker is one of the major challenges for prostate specific membrane antigen negative (PSMA (-)) prostate cancer therapy.
|
31451114 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate the therapeutic potential of specific-oncolysis and suicide gene therapy for AI-PSA/PSMA-positive prostate cancer gene therapy.
|
18772902 |
2009 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, a phase III randomized, controlled trial provided unequivocal evidence of the effectiveness of 177Lu-DOTATATE for treatment of neuroendocrine tumors, and there have been multiple reports of the benefits of prostate-specific membrane antigen targeted PET imaging and radio-ligand therapy in prostate cancer.
|
31718092 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, <sup>64</sup> Cu-PSMA-617-PET demonstrated to be feasible for imaging prostate cancer for both the primary tumor site and metastases.
|
31042811 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The semi-quantitative parameters of <sup>68</sup>Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model.
|
29717333 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that this chimeric antigen receptor T-cells could kill PSMA-positive prostate cancer specifically.
|
29275833 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts.
|
30488099 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
|
28957842 |
2017 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate specific membrane antigen (PSMA) expression correlates with prostate cancer grade and is increased in hormone-refractory prostate cancer.
|
18247401 |
2008 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify locations of recurrence after radical prostatectomy (RP) with prostate-specific antigen (PSA) <2 by Gallium-68 prostate-specific membrane antigen (PSMA)-11 Positron Emission Tomography (PET) imaging, and to determine whether standard nodal radiation fields would cover the location of prostate cancer recurrence.
|
30928607 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For evaluating the advantages and disadvantages and the comparability, we conducted a prospective head-to-head comparison on F-fluciclovine and Ga-PSMA-11 in patients with biochemical recurrence of PCa.
|
31283605 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusion This study found that <sup>68</sup>Ga-PSMA-11 PET can be used to identify prostate cancer, while MR imaging provides detailed anatomic guidance.
|
29786490 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A limitation of using <sup>68</sup>Ga-labeled prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) for detection and staging of prostate cancer is a frequently observed halo artifact around the urinary bladder caused by inaccurate scatter correction (SC) of PET data.
|
30979819 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 139 patients underwent Ga-68-PSMA-11 PET imaging for prostate cancer: 47 non-time-of-flight (non-TOF) PET/computed tomography, 51 PET/magnetic resonance imaging (MRI) using the standard TOF scatter correction algorithm, and 41 PET/MRI using an improved TOF scatter correction algorithm.
|
31749411 |
2020 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA), an established enzyme-biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications.
|
20452720 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We consider that these findings provide a basis for the development of systemically delivered PSMA/iNOS or hOC/iNOS targeting early stage and advanced prostate cancer.
|
20821746 |
2010 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [<sup>68</sup>Ga]PSMA I&T and comparison with published data of [<sup>68</sup>Ga]PSMA HBED-CC.
|
27896369 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the diagnostic value of PSMA PET/CT in the diagnosis of recurrent PCa with low prostate-specific antigen (PSA) levels.
|
27893589 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that <sup>68</sup>Ga PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer.
|
28795303 |
2018 |